DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LEUSTATIN

« Back to Dashboard

Clinical Trials for Leustatin

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00667329	Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab	Active, not recruiting	M.D. Anderson Cancer Center	N/A	The goal of this clinical research study is to see how well the drugs 2CdA, cyclophosphamide, and rituximab (rituxan) shrink a lymphoma called Waldenstrom's macroglobulinemia. After these drugs are given for 2 courses, a second goal is to see how long a remission lasts. A third goal is to see how often repeat remissions can be achieved when the lymphoma returns later and the same drugs are restarted.
NCT01513603	Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia	Unknown status	New York Medical College	Phase 2	CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.
NCT03012672	Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm	Not yet recruiting	National Cancer Institute (NCI)	N/A	This randomized pilot trial studies how well higher or lower dose cladribine, cytarabine, and mitoxantrone work in treating medically less fit patients with newly diagnosed acute myeloid leukemia or myeloid neoplasm. Drugs used in chemotherapy, such as cladribine, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cladribine, cytarabine, and mitoxantrone at higher or lower dose may work better in treating patients with newly diagnosed acute myeloid leukemia.

Clinical Trial Conditions for Leustatin

Condition Name

Condition Name for Leustatin
Intervention	Trials
Acute Myeloid Leukemia	4
Myeloproliferative Neoplasm	1
Chronic Myelogenous Leukemia	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Leustatin
Intervention	Trials
Leukemia, Myeloid	5
Leukemia	5
Leukemia, Myeloid, Acute	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Leustatin

Trials by Country

Trials by Country for Leustatin
Location	Trials
United States	6

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Leustatin
Location	Trials
Texas	3
Washington	2
New York	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Leustatin

Clinical Trial Phase

Clinical Trial Phase for Leustatin
Clinical Trial Phase	Trials
Phase 2	3
Phase 1/Phase 2	1
N/A	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Leustatin
Clinical Trial Phase	Trials
Not yet recruiting	2
Recruiting	2
Unknown status	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Leustatin

Sponsor Name

Sponsor Name for Leustatin
Sponsor	Trials
National Cancer Institute (NCI)	4
M.D. Anderson Cancer Center	3
Fred Hutchinson Cancer Research Center	2

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Leustatin
Sponsor	Trials
Other	6
NIH	4

Export unavailable in trial.
Subscribe for complete access.